1-2 of 2
Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA
Close
Sort by
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation

Genevieve Douglas, B.App.Sc MBBS FRACP FRCPA, Michelle K Yong, MBBS, FRACP, MPH, PhD, Shio Yen Tio, MBBS, FRACP, Maggie Chau, BPharm(Hons) MClinPharm MBusMgt BCOP, Joe Sasadeusz, MBBS FRACP PhD, Monica Slavin, MBBS FRACP, Mingdi Xie, BNurs GradDip, David Ritchie, MB ChB, PhD FRACP, FRCPA, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-141764
Published: 2020